Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March:
- A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025
- A presentation at the TD Cowen 45th Annual Health Care Conference at 1:50 p.m. ET on Monday, March 3, 2025 in Boston, MA
- A fireside chat at the Leerink Global Healthcare Conference at 8:40 a.m. ET on Monday, March 10, 2025 in Miami, FL
A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Company’s website at , where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit or follow the Company on or , formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
Media Contact
David Rosen
Argot Partners
